Novartis supported the expansion application with topline data from the Phase III NATALEE trial, in which treatment with Kisqali led to a significant improvement in disease-free survival versus standard adjuvant endocrine therapy alone, according to the company
When administered as a compounded medication, Olympias Glutathione can be utilized as a stand-alone IV infusion, or as an IM injection at-home or in the clinic
For calculations of peptide intensity differences and associations with beta cell function, a false discovery rate (FDR) of 0.05 was applied after multiple hypothesis correction using the BenjaminiHochberg procedure
The peptide has an interesting research story, and it also sits in a complicated regulatory position that you should understand before considering it
[DOI] [PMC free article] [PubMed] [Google Scholar] Harrison PM, Keays R, Bray GP, Alexander GJ, Williams R